Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine/meloxicam - Heron Therapeutics

Next Previous
Drug Profile

Bupivacaine/meloxicam - Heron Therapeutics

Alternative Names: Bupivacaine/meloxicam extended release; HTX-002/HTX-009; HTX-009/HTX-002; HTX-011; HTX-011A; HTX-011B; Meloxicam/bupivacaine; Meloxicam/bupivacaine extended release; ZYNRELEF

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heron Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Anilides; Antipyretics; Local anaesthetics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pipecolic acids; Piperidines; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative pain

Most Recent Events

  • 12 Mar 2024 Belite Bio announces intention to submit Prior Approval Supplement in Q2 2024
  • 12 Mar 2024 Heron Therapeutics anticipates launch of Bupivacaine/meloxicam in the second half of 2024
  • 23 Jan 2024 The US FDA approves bupivacaine/meloxicam for Postoperative pain in soft tissue and orthopaedic surgical procedures
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top